SS Innovations International (NASDAQ: SSII) announced it has been named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, which recognizes a company demonstrating excellence in innovation, commercial success, industry leadership and positive societal impact. The company said the award reflects growing adoption of its SSi Mantra surgical robotic system, which it believes is gaining traction for its advanced technology, user-friendly design, training capabilities and cost efficiency.
As of June 22, 2026, SS Innovations reported that 11,719 multi-specialty procedures had been performed using the SSi Mantra system, including 612 cardiac procedures, 175 telesurgeries and 212 pediatric surgeries. The company also said approximately 2,100 physicians have been trained on the platform, which has been used for more than 170 procedure types and has received regulatory approval in 14 countries.
Questions around this news
How many procedures and physician trainings did SS Innovations report for its surgical robotic system?
As of June 22, 2026, the company reported 11,719 procedures across multiple specialties using the system. It also reported that approximately 2,100 physicians had been trained on the platform, which it said had been used for more than 170 procedure types and had regulatory approval in 14 countries.
What is telesurgery?
Telesurgery is surgery in which a surgeon operates on a patient remotely using robotic equipment and a communications link. The surgeon controls instruments from a separate location, while the robotic system carries out those movements at the patient’s side. Its use depends on suitable technology, clinical protocols and reliable connectivity.
What does regulatory approval mean for a medical device?
Regulatory approval means a relevant health authority has authorized a medical device for specified uses in its jurisdiction, following a review under that jurisdiction’s rules. The approval’s scope can vary by country and may cover particular indications or conditions of use; it does not necessarily mean a device is authorized for every application.
To view the full press release, visit https://ibn.fm/XWdRe
About SS Innovations
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
Visit the Company’s website at ssinnovations.com for more information and updates.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- SS Innovations International, Inc.
- Ticker
- NASDAQ: SSII
- Announcement
- Award
Key figures
- Procedures performed using the SSi Mantra system
- 11,719
- Cardiac procedures
- 612
- Telesurgeries
- 175
- Pediatric surgeries
- 212
- Physicians trained
- approximately 2,100
- Countries with regulatory approval
- 14
